123 related articles for article (PubMed ID: 35171570)
1. Liposomal Targeting Modifies Endosomal Escape: Design and Mechanistic Implications.
Mejia F; Khan S; Bilgicer B
ACS Biomater Sci Eng; 2022 Mar; 8(3):1067-1073. PubMed ID: 35171570
[TBL] [Abstract][Full Text] [Related]
2. Identification and optimization of tunable endosomal escape parameters for enhanced efficacy in peptide-targeted prodrug-loaded nanoparticles.
Mejia F; Khan S; Omstead DT; Minetos C; Bilgicer B
Nanoscale; 2022 Jan; 14(4):1226-1240. PubMed ID: 34993530
[TBL] [Abstract][Full Text] [Related]
3. Strategies in the design of endosomolytic agents for facilitating endosomal escape in nanoparticles.
Ahmad A; Khan JM; Haque S
Biochimie; 2019 May; 160():61-75. PubMed ID: 30797879
[TBL] [Abstract][Full Text] [Related]
4. pH-responsive cationic liposome for endosomal escape mediated drug delivery.
Rayamajhi S; Marchitto J; Nguyen TDT; Marasini R; Celia C; Aryal S
Colloids Surf B Biointerfaces; 2020 Apr; 188():110804. PubMed ID: 31972443
[TBL] [Abstract][Full Text] [Related]
5. Incorporation of Endosomolytic Peptides with Varying Disruption Mechanisms into EGFR-Targeted Protein Conjugates: The Effect on Intracellular Protein Delivery and EGFR Specificity in Breast Cancer Cells.
Lieser RM; Li Q; Chen W; Sullivan MO
Mol Pharm; 2022 Feb; 19(2):661-673. PubMed ID: 35040326
[TBL] [Abstract][Full Text] [Related]
6. Octaarginine- and octalysine-modified nanoparticles have different modes of endosomal escape.
El-Sayed A; Khalil IA; Kogure K; Futaki S; Harashima H
J Biol Chem; 2008 Aug; 283(34):23450-61. PubMed ID: 18550548
[TBL] [Abstract][Full Text] [Related]
7. Endosomal Escape of Bioactives Deployed via Nanocarriers: Insights Into the Design of Polymeric Micelles.
Butt AM; Abdullah N; Rani NNIM; Ahmad N; Amin MCIM
Pharm Res; 2022 Jun; 39(6):1047-1064. PubMed ID: 35619043
[TBL] [Abstract][Full Text] [Related]
8. Probing Endosomal Escape Using pHlexi Nanoparticles.
Kongkatigumjorn N; Cortez-Jugo C; Czuba E; Wong AS; Hodgetts RY; Johnston AP; Such GK
Macromol Biosci; 2017 Apr; 17(4):. PubMed ID: 27786422
[TBL] [Abstract][Full Text] [Related]
9. Controlling endosomal escape using nanoparticle composition: current progress and future perspectives.
Cupic KI; Rennick JJ; Johnston AP; Such GK
Nanomedicine (Lond); 2019 Jan; 14(2):215-223. PubMed ID: 30511881
[TBL] [Abstract][Full Text] [Related]
10. Endosomal escape of delivered mRNA from endosomal recycling tubules visualized at the nanoscale.
Paramasivam P; Franke C; Stöter M; Höijer A; Bartesaghi S; Sabirsh A; Lindfors L; Arteta MY; Dahlén A; Bak A; Andersson S; Kalaidzidis Y; Bickle M; Zerial M
J Cell Biol; 2022 Feb; 221(2):. PubMed ID: 34882187
[TBL] [Abstract][Full Text] [Related]
11. Endosomal Size and Membrane Leakiness Influence Proton Sponge-Based Rupture of Endosomal Vesicles.
Vermeulen LMP; Brans T; Samal SK; Dubruel P; Demeester J; De Smedt SC; Remaut K; Braeckmans K
ACS Nano; 2018 Mar; 12(3):2332-2345. PubMed ID: 29505236
[TBL] [Abstract][Full Text] [Related]
12. A Virus-Mimicking, Endosomolytic Liposomal System for Efficient, pH-Triggered Intracellular Drug Delivery.
Chen S; Chen R
ACS Appl Mater Interfaces; 2016 Aug; 8(34):22457-67. PubMed ID: 27512894
[TBL] [Abstract][Full Text] [Related]
13. Development of a novel nanoparticle by dual modification with the pluripotential cell-penetrating peptide PepFect6 for cellular uptake, endosomal escape, and decondensation of an siRNA core complex.
Mitsueda A; Shimatani Y; Ito M; Ohgita T; Yamada A; Hama S; Gräslund A; Lindberg S; Langel Ü; Harashima H; Nakase I; Futaki S; Kogure K
Biopolymers; 2013 Nov; 100(6):698-704. PubMed ID: 23893316
[TBL] [Abstract][Full Text] [Related]
14. Quantifying the Endosomal Escape of pH-Responsive Nanoparticles Using the Split Luciferase Endosomal Escape Quantification Assay.
Beach MA; Teo SLY; Chen MZ; Smith SA; Pouton CW; Johnston APR; Such GK
ACS Appl Mater Interfaces; 2022 Jan; 14(3):3653-3661. PubMed ID: 34964593
[TBL] [Abstract][Full Text] [Related]
15. Designing Mesoporous Silica Nanoparticles to Overcome Biological Barriers by Incorporating Targeting and Endosomal Escape.
Gisbert-Garzarán M; Lozano D; Matsumoto K; Komatsu A; Manzano M; Tamanoi F; Vallet-Regí M
ACS Appl Mater Interfaces; 2021 Mar; 13(8):9656-9666. PubMed ID: 33596035
[TBL] [Abstract][Full Text] [Related]
16. Fluorescence microscopy colocalization of lipid-nucleic acid nanoparticles with wildtype and mutant Rab5-GFP: A platform for investigating early endosomal events.
Majzoub RN; Chan CL; Ewert KK; Silva BF; Liang KS; Safinya CR
Biochim Biophys Acta; 2015 Jun; 1848(6):1308-18. PubMed ID: 25753113
[TBL] [Abstract][Full Text] [Related]
17. Transfection mechanisms of polyplexes, lipoplexes, and stealth liposomes in α₅β₁ integrin bearing DLD-1 colorectal cancer cells.
Adil MM; Erdman ZS; Kokkoli E
Langmuir; 2014 Apr; 30(13):3802-10. PubMed ID: 24635537
[TBL] [Abstract][Full Text] [Related]
18. Engineering liposomal nanoparticles for targeted gene therapy.
Zylberberg C; Gaskill K; Pasley S; Matosevic S
Gene Ther; 2017 Aug; 24(8):441-452. PubMed ID: 28504657
[TBL] [Abstract][Full Text] [Related]
19. Liposomes: from a clinically established drug delivery system to a nanoparticle platform for theranostic nanomedicine.
Al-Jamal WT; Kostarelos K
Acc Chem Res; 2011 Oct; 44(10):1094-104. PubMed ID: 21812415
[TBL] [Abstract][Full Text] [Related]
20. Delivering anti-cancer drugs with endosomal pH-sensitive anti-cancer liposomes.
Moku G; Gulla SK; Nimmu NV; Khalid S; Chaudhuri A
Biomater Sci; 2016 Apr; 4(4):627-38. PubMed ID: 26806172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
